The way property values are displayed:
The way concept relations are shown:
The way concept relations are shown:
Dactinomycin
Hierarchy: | ∟ ∟ ∟ ∟ Dactinomycin 40 coordinate concepts∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Faloidin | ∟ ∟ ∟ ∟ ∟ ∟ Nisin | ∟ ∟ ∟ ∟ ∟ ∟ Viomycin | ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Flaviner | ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Dactinomycin 40 coordinate concepts∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Faloidin | ∟ ∟ ∟ ∟ ∟ ∟ Nisin | ∟ ∟ ∟ ∟ ∟ ∟ Viomycin | ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Flaviner | ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Dactinomycin 40 coordinate concepts∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Faloidin | ∟ ∟ ∟ ∟ ∟ ∟ Nisin | ∟ ∟ ∟ ∟ ∟ ∟ Viomycin | ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Flaviner | ∟ ∟ ∟ ∟ ∟ ∟ |
Broader terms: | |
historyNote*: | 66; ACTINOMYCIN was heading 1963-95
X |
publicMeSHNote*: | 66; ACTINOMYCIN was heading 1963-95
X |
Scope note: | A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
X |
activeMeSHYear*: | |
dateCreated*: | 1999-01-01X |
dateEstablished*: | 1966-01-01X |
dateRevised*: | 2005-06-30X |
recordAuthorizer*: | sjnX |
recordMaintainer*: | exlX |
recordOriginator*: | NLMX |
Type: | |
Coordinate terms: | |
URI: | |
Labels and equivalent concepts: | Daktinomysiini (fi) XAktinomysiini D (fi, replaced) Daktinomycin (sv) Actinomycin (sv, replaced) Cosmegen (sv, replaced) MSD Brand of Dactinomycin (en, replaced) Merck Sharp & Dohme Brand of Dactinomycin (en, replaced) Merck Frosst Brand of Dactinomycin (en, replaced) Merck Brand of Dactinomycin (en, replaced) Cosmegen Lyovac (en, replaced) Lemery Brand of Dactinomycin (en, replaced) Lyovac-Cosmegen (en, replaced) Meractinomycin (en, replaced) Actinomycin D (en, replaced) |
Share: |
Loading results...